Samuel Bates Martin - Aug 10, 2021 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
SVP and CFO
Signature
/s/ Anthony S. Marucci, attorney in fact for Samuel Bates Martin
Stock symbol
CLDX
Transactions as of
Aug 10, 2021
Transactions value $
-$207
Form type
4
Date filed
8/12/2021, 10:00 AM
Previous filing
Jun 21, 2021
Next filing
Nov 17, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDX Common Stock Options Exercise $92.9K +10.3K +95.97% $9.02 21K Aug 10, 2021 Direct F1, F2
transaction CLDX Common Stock Sale -$93K -2.06K -9.77% $45.25 19K Aug 10, 2021 Direct F1, F3
transaction CLDX Common Stock Options Exercise $30.8K +11.1K +58.37% $2.78* 30.1K Aug 10, 2021 Direct
transaction CLDX Common Stock Sale -$30.9K -682 -2.27% $45.25 29.4K Aug 10, 2021 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option Options Exercise $0 -10.3K -39.12% $0.00 16K Aug 10, 2021 Common Stock 10.3K $9.02 Direct F2, F4
transaction CLDX Incentive Stock Option Options Exercise $0 -11.1K -25.77% $0.00 31.9K Aug 10, 2021 Common Stock 11.1K $2.78 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F2 This option was previously reported as covering 395,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.
F3 Represents shares sold upon exercise of option in payment of exercise price pursuant to broker-assisted cashless exercise transaction.
F4 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
F5 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.